C46H82Cu2N2P2S4, triclinic, P1̄ (no. 2), a = 11.6189(2) Å, b = 12.2846(2) Å, c = 18.1744(2) Å, α = 97.3210(10)°, β = 106.3080(10)°, γ = 99.312(2)°, V = 2415.65(7) Å3, Z = 2, Rgt(F) = 0.025, wRref(F2) = 0.066, T = 100(2) K
The title trinuclear compound, [Cu3(C5H8NS2)Cl2(C6H15P)3], has the dithiocarbamate ligand symmetrica...
C62H70Cu3N4O32, monoclinic, C2/c (no. 15), a = 44.710(7) Å, b = 12.8847(17) Å, c = 11.9901(18) Å, β ...
C52H36N4O12Pb2 ⋅ H2O, monoclinic, P21/n (no. 19), a = 13.7767(1) Å, b = 7.9925(1) Å, c = 21.2490(2) ...
C22H46Ag2N2P2S4, triclinic, P1Ì., (no. 2), a = 10.2008(3) Å, b = 12.2058(3) Å, c = 13.2466(4) Å, α =...
C47H45Cl2N9Cu3O6, monoclinic, C2/c (no. 15), a = 24.084(9) Å, b = 12.152(5) Å, c = 17.404(7) Å, β = ...
C50H64Cu4N8O26, triclinic, P1̄ (no. 2), a = 11.0000(3) Å, b = 11.2890(3) Å, c = 12.4370(4) Å, α = 10...
C40H44CuO4Fe2N6, triclinic, P1̄ (no. 2), a = 7.4758(4) Å, b = 7.7447(5) Å, c = 16.2929(10) Å, α = 87...
C16H16CuN2S4, monoclinic, P21/n (no. 14), a = 7.6067(2) Å, b = 6.5835(2) Å, c = 18.5042(5) Å, β = 97...
C57H54BCuF4N3P2, monoclinic, P21/c (no. 14), a = 11.6379(12) Å, b = 20.173(2) Å, c = 21.786(2) Å, β ...
C49H40BCu2F4Fe2N5O5, triclinic, P1̄ (no. 2), a = 11.526(2) Å, b = 12.902(2) Å, c = 15.469(3) Å, α = ...
C50H48BCuF4N4P2, orthorhombic, Pnma (no. 62), a = 24.166(2) Å, b = 19.5652(18) Å, c = 9.6477(9) Å, Z...
C80H96N32Cu11Br14, triclinic, P1̄ (no. 2), a = 11.370(2) Å, b = 14.287(3) Å, c = 17.621(3) Å, α = 85...
C52H42CuN4O4, monoclinic, I12/c1 (no. 15), a = 21.8573(13) Å, b = 5.8605(4) Å, c = 33.683(2) Å, β = ...
C48H32N26Bi2, triclinic, P1‾$\overline{1}$ (no. 2), a = 9.781(5) Å, b = 11.667(6) Å, c = 11.973(7) Å...
C15H17CdN5O2S2, triclinic, P1‾$P‾{1}$ (no. 2), a = 9.6685(4) Å, b = 10.4511(4) Å, c = 11.2840...
The title trinuclear compound, [Cu3(C5H8NS2)Cl2(C6H15P)3], has the dithiocarbamate ligand symmetrica...
C62H70Cu3N4O32, monoclinic, C2/c (no. 15), a = 44.710(7) Å, b = 12.8847(17) Å, c = 11.9901(18) Å, β ...
C52H36N4O12Pb2 ⋅ H2O, monoclinic, P21/n (no. 19), a = 13.7767(1) Å, b = 7.9925(1) Å, c = 21.2490(2) ...
C22H46Ag2N2P2S4, triclinic, P1Ì., (no. 2), a = 10.2008(3) Å, b = 12.2058(3) Å, c = 13.2466(4) Å, α =...
C47H45Cl2N9Cu3O6, monoclinic, C2/c (no. 15), a = 24.084(9) Å, b = 12.152(5) Å, c = 17.404(7) Å, β = ...
C50H64Cu4N8O26, triclinic, P1̄ (no. 2), a = 11.0000(3) Å, b = 11.2890(3) Å, c = 12.4370(4) Å, α = 10...
C40H44CuO4Fe2N6, triclinic, P1̄ (no. 2), a = 7.4758(4) Å, b = 7.7447(5) Å, c = 16.2929(10) Å, α = 87...
C16H16CuN2S4, monoclinic, P21/n (no. 14), a = 7.6067(2) Å, b = 6.5835(2) Å, c = 18.5042(5) Å, β = 97...
C57H54BCuF4N3P2, monoclinic, P21/c (no. 14), a = 11.6379(12) Å, b = 20.173(2) Å, c = 21.786(2) Å, β ...
C49H40BCu2F4Fe2N5O5, triclinic, P1̄ (no. 2), a = 11.526(2) Å, b = 12.902(2) Å, c = 15.469(3) Å, α = ...
C50H48BCuF4N4P2, orthorhombic, Pnma (no. 62), a = 24.166(2) Å, b = 19.5652(18) Å, c = 9.6477(9) Å, Z...
C80H96N32Cu11Br14, triclinic, P1̄ (no. 2), a = 11.370(2) Å, b = 14.287(3) Å, c = 17.621(3) Å, α = 85...
C52H42CuN4O4, monoclinic, I12/c1 (no. 15), a = 21.8573(13) Å, b = 5.8605(4) Å, c = 33.683(2) Å, β = ...
C48H32N26Bi2, triclinic, P1‾$\overline{1}$ (no. 2), a = 9.781(5) Å, b = 11.667(6) Å, c = 11.973(7) Å...
C15H17CdN5O2S2, triclinic, P1‾$P‾{1}$ (no. 2), a = 9.6685(4) Å, b = 10.4511(4) Å, c = 11.2840...
The title trinuclear compound, [Cu3(C5H8NS2)Cl2(C6H15P)3], has the dithiocarbamate ligand symmetrica...
C62H70Cu3N4O32, monoclinic, C2/c (no. 15), a = 44.710(7) Å, b = 12.8847(17) Å, c = 11.9901(18) Å, β ...
C52H36N4O12Pb2 ⋅ H2O, monoclinic, P21/n (no. 19), a = 13.7767(1) Å, b = 7.9925(1) Å, c = 21.2490(2) ...